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Abstract
Background: Current and past pertussis epidemiology in the two parts of Germany is compared
in the context of different histories of vaccination recommendations and coverage to better
understand patterns of disease transmission.
Methods: Available regional pertussis surveillance and vaccination coverage data, supplemented
by a literature search for published surveys as well as official national hospital and mortality
statistics, were analyzed in the context of respective vaccination recommendations from 1964
onwards.
Results: Routine childhood pertussis vaccination was recommended in the German Democratic
Republic (GDR) from 1964 and in former West German states (FWG) from 1969, but withdrawn
from 1974–1991 in FWG. Pertussis incidence declined to <1 case/100.000 inhabitants in GDR prior
to reunification in 1991, while in FWG, where pertussis was not notifiable after 1961, incidence
was estimated at 160–180 cases/100.000 inhabitants in the 1970s-1980s. Despite recommendations
for universal childhood immunization in 1991, vaccination coverage decreased in former East
German States (FEG) and increased only slowly in FWG. After introduction of acellular pertussis
vaccines in 1995, vaccination coverage increased markedly among younger children, but remains
low in adolescents, especially in FWG, despite introduction of a booster vaccination for 9–17 year
olds in 2000. Reported pertussis incidence increased in FEG to 39.3 cases/100.000 inhabitants in
2007, with the proportion of adults increasing from 20% in 1995 to 68% in 2007. From 2004–2007,
incidence was highest among 5–14 year-old children, with a high proportion fully vaccinated
according to official recommendations, which did not include a preschool booster until 2006.
Hospital discharge statistics revealed a ~2-fold higher pertussis morbidity among infants in FWG
than FEG.
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Conclusion: The shift in pertussis morbidity to older age groups observed in FEG is similar to
reports from other countries with longstanding vaccination programs and suggests that additional
booster vaccination may be necessary beyond adolescence. The high proportion of fully vaccinated
cases in older children in FEG suggests waning immunity 5–10 years after primary immunisation in
infancy. The higher incidence of pertussis hospitalisations in infants suggests a stronger force of
infection in FWG than FEG. Nationwide pertussis reporting is required for better evaluation of
transmission patterns and vaccination policy in both parts of Germany.
Background
An increase in the incidence of pertussis, particularly
among older children, adolescents and adults, was
observed since the 1980s in the United States and since
the 1990s in Canada and several European countries, all
with high childhood pertussis vaccination coverage [1-5].
Pertussis is most severe among infants, who have the
highest risk of complications, hospitalization and death
[6-8]. Although the disease is frequently milder among
older children, adolescents and adults, a protracted course
is the rule and complications such as pneumonia, urinary
incontinence, weight loss and rib fractures may occur [9-
12]. Several factors contribute to the persistent circulation
of the infectious agent, Bordetella pertussis, despite immu-
nization programs, the most important of which is wan-
ing of pertussis-specific immunity after about 7 to 20 years
after natural infection and 4 to 12 years after immuniza-
tion [13,14]. Furthermore, B. pertussis is highly conta-
gious, with a basic reproductive number of 12–17 [15].
Because of the non-specific initial presentation of the ill-
ness and because the infection may not cause the full-
blown clinical picture in immunized individuals or those
with previous natural infection, the diagnosis may be
delayed or overlooked, thereby leading to prolonged
transmission. Thus the susceptibility to and transmission
of the disease is influenced by current and past vaccina-
tion coverage, vaccination schedule, type of vaccine in use
and social mixing patterns.
Vaccination recommendations, resulting vaccination cov-
erage and the incidence of pertussis differed markedly in
the former German Democratic Republic (GDR) and the
former West Germany (FWG), with differences persisting
for some time after reunification. Therefore, the aim of
our paper is to compare the epidemiology of pertussis in
the two parts of Germany to better understand patterns of
disease transmission and optimize prevention efforts.
Methods
Official pertussis vaccination recommendations in the
GDR, FWG and the reunited Germany were reviewed. The
Standing Committee on Vaccination (STIKO) was respon-
sible for vaccination recommendations in FWG since
1972, and since 1991 also in the reunited Germany. Prior
to 1972, a "Pertussis-Committee" of pediatric and infec-
tious disease specialists made recommendations in FWG
[16]. Recommendations are generally adopted by the
individual federal states, which can, however, deviate
from them. In the former GDR the ministry of health was
responsible for making vaccination recommendations
[16].
Data on pertussis vaccination coverage in Germany rou-
tinely obtained from obligatory medical examinations
performed by the regional health authorities at school
entry (children aged 5 to 7 years) have been made availa-
ble to RKI by the federal states since 1998. In addition,
Medline, Embase and Embase Alert data bases were
searched for vaccination coverage studies in Germany
using the free text search terms [(pertussis or whooping
cough) AND Germany AND (vaccination coverage or vac-
cination rate)].
The following official data sources were used to obtain
data on the incidence of pertussis: Pertussis was statutorily
notifiable from 1947 to 1961 in Germany and data were
published by the Federal Statistical Office [17]. In FWG,
notification was no longer required as of 1962; thus sur-
veillance data are lacking. In GDR pertussis was a statuto-
rily notifiable disease and aggregate data for 1962–1990
were published by the Statistical Office of the German
Democratic Republic. Reporting continued after reunifica-
tion in five former East German states (referred to as FEG:
Brandenburg (BB), Mecklenburg-Western Pomerania
(MV), Saxony (SN), Saxony-Anhalt (ST), Thuringia (TH),
but not East Berlin, counted as part of FWG after reunifi-
cation in 1991). These 5 states transmitted case-based
data with a minimal variable set to the Robert Koch-Insti-
tute (RKI), the federal institution responsible for disease
control and prevention, from 1995 to 2000, enabling a
basic demographic analysis. Pertussis was not made a
notifiable disease under the new German Protection
Against Infection Law implemented in 2001. However,
FEG continued to require statutory reporting of pertussis
according to state-specific regulations. From 2001
onwards notified case-based data were transmitted to RKI,
although these were incomplete in 2001.
A uniform case definition was applied from 2002
onwards [18], thus a detailed analysis of FEG surveillanceBMC Infectious Diseases 2009, 9:22 http://www.biomedcentral.com/1471-2334/9/22
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data was undertaken for the period January 2002 to
December 2007 according to region, age and sex, hospi-
talization and vaccination status, as well as outbreaks.
According to the surveillance case definition in place from
2002–2008, a clinical case must manifest at least one of
the following symptoms for at least 2 weeks: i. cough
attacks, ii. whooping, iii. post-tussive vomiting or – in
infants – iv. episodes of apnea. Laboratory diagnosis, ini-
tiated at the discretion of the physician, consists of cul-
tural isolation or detection of B. pertussis by PCR in
nasopharyngeal swabs or secretions or serological diagno-
sis by means of an elevated pertussis-specific IgA- anti-
body concentration in a single serum sample or a 4-fold
increase in IgG- or IgA- pertussis-specific antibodies using
any commercially available test kit (e.g. Serion ELISA clas-
sic measuring IgG-[PT, FHA (filamentous hemagglutinin)]
and IgA- (PT, FHA) antibodies, Genzyme Virotech GmbH
ELISA measuring IgG- and IgA-antibodies against PT, or
Bordetella pertussis IgG Virastripe®, an immunoassay also
measuring IgG-antibodies against PT and FHA (produced
by Viramed) [19]. The majority of the 18,080 cases noti-
fied to RKI between January 2002 and December 2007
were laboratory confirmed (93.8%); 1.9% fulfilled the
clinical case definition and were epidemiologically linked
to a laboratory confirmed case and 4.4% solely fulfilled
the clinical case definition. Of the laboratory confirmed
cases, 172 (1.0%) were diagnosed by culture, 1769
(9.8%) by PCR, 4861 (26.9%) by an increase in pertussis-
specific antibodies, and 10,153 (56.2%) by a high con-
centration of pertussis-specific IgA-antibodies in a single
serum sample. Detailed data on the vaccination status of
cases were available from 2004 onwards for 78% of noti-
fied cases. A case was defined as adequately vaccinated if
3 doses of pertussis vaccine had been given with the third
dose less than one year prior to disease onset or if at least
4 doses had been given with the last dose = 10 years prior
to disease onset. Doses received within 3 weeks prior to
disease onset were not counted.
Detailed hospital discharge and mortality data for pertus-
sis (principal diagnosis and underlying cause of death,
respectively) were provided by the German Federal Statis-
tical Office http://www.gbe-bund.de/gbe10/isgbe.prc_
impressum?p_uid=gast&p_aid=23980486&p_sprache=E.
In addition to official data on pertussis disease burden,
Medline, Embase and Embase Alert data bases were
searched for further sources on pertussis incidence, such as
sentinel studies or regional surveys, in Germany using the
search terms [(pertussis or whooping cough) AND Ger-
many AND (incidence or disease burden or morbidity)].
Results
Vaccination recommendations prior to 1991
In GDR, pertussis vaccination was mandatory for all chil-
dren from 1964 onwards [16]. In the 1980s three doses of
whole cell vaccine were recommended at the age of 2, 3,
and 6 months. A fourth dose was recommended in the
third year of life [20]. Between 1971 and 1979 a fifth dose
was recommended prior to school entry [21,22].
In FWG routine pertussis vaccination with whole cell vac-
cine was recommended for infants and toddlers from
1969 until 1974 [16]. As in some other countries, such as
the UK, this recommendation was withdrawn by STIKO
from 1974 [23] to 1991 due to anecdotal reports of severe
adverse effects affecting the central nervous system. Dur-
ing this period, pertussis vaccination was only recom-
mended for high risk children prior to their second
birthday.
Vaccination coverage prior to 1991
Vaccination coverage in preschool children (≥ 4 doses)
was >90% in GDR during the 1980s [20]. Surveys and esti-
mates based on vaccine sales data in the 1970s and 1980s
in FWG revealed a childhood vaccination coverage of 50–
60% in southern and 2–20% in northern regions [24].
Pertussis incidence prior to 1991
Pertussis incidence based on reported cases in GDR
declined to <1/100,000 population in the late 1980s
prior to reunification [25,26] (Fig. 1). Incidence esti-
mates in FWG based on regional surveys in the 1970s
and 1980s ranged from 160–180 cases/100,000 popula-
tion [25,27]. Among children <6 years, pertussis inci-
dence was estimated at 4%–6% annually between 1987
and 1990 [28].
Vaccination recommendations after 1990
In 1991 pertussis vaccination for all infants with whole-
cell pertussis vaccine was again recommended by STIKO
in the reunified Germany, with four vaccine doses at the
ages of 2, 3, 4 and 11 to 14 months [29]. In 1993 STIKO
recommended catch-up vaccination for all children up to
their sixth birthday [30]. In 1995 acellular vaccines with 2
(pertussis toxin (PT) and filamentous hemagglutinin
(FHA)), 3 (PT, FHA and pertactin (PRN)) or 5 compo-
nents (PT, FHA, PRN and fimbriae 2 and 3) were licensed
in Germany. These were exclusively recommended from
1997 onwards. In 2000 a single booster vaccination was
recommended for children aged 9 to 17 years [31]. In
2003 STIKO recommended pertussis vaccination for child
care workers and health care workers [32] and in 2004
additionally for adults with close contact to infants (par-
ents and other care givers) prior to the birth of the infant
(cocoon strategy) [33]. An additional booster dose at the
age of 5–6 years was recommended by STIKO in January,
2006. In Saxony, the state committee on vaccination
(SIKO) recommended a preschool booster already in
1998 and booster vaccinations for adults at 10 year inter-
vals in 2007 [34].BMC Infectious Diseases 2009, 9:22 http://www.biomedcentral.com/1471-2334/9/22
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Vaccination coverage after 1990
Pertussis vaccine uptake increased only very gradually in
FWG after 1991 prior to the broad introduction of acellu-
lar vaccines in 1995, which were exclusively recom-
mended from 1998 onwards. In FEG vaccine uptake
actually decreased between 1991 and 1995. An interview
survey performed by Kirschner et al. in 1994–1995 [35]
revealed a vaccination coverage at 2 years of age (at least 4
vaccine doses) of 8.8% (children born in 1989) and
46.6% (children born in 1992) in FWG and 65.5% (chil-
dren born in 1989) and 46.3% (children born in 1992) in
FEG. Of children born in 1992, 92.5% had begun the vac-
cination series in FEG but only 76.7% in FWG. From 1998
until 2007, vaccination coverage of children at school
entry increased steadily in FEG from 85.8% to 95.9% and
in FWG from 57.7% to 92.2%.
Vaccination coverage was also assessed in the recent Ger-
man Health Interview and Examination Survey for Chil-
dren and Adolescents (KiGGS), which examined a
representative sample of 17,461 children from 0 to 17
years between May 2003 and May 2006, of whom 16,460
(93.1%) presented their vaccination record [36,37]. Per-
tussis vaccination coverage (at least 4 vaccine doses) was
84.9% (95% CI: 81.7%–87.6%) at the age of 2 years and
peaked at 90.4% (95% CI: 89.2–91.5%) in 3 to 6 year old
children (FEG: 91.9% (95% CI: 89.9–93.5%), FWG: 90.1
(95% CI: 88.7–91.3%). In older children, vaccination
coverage decreased markedly with age to 36.1% (95% CI:
32.0–40.4%) in 14 to 17-year old adolescents, who had a
significantly higher vaccination coverage in FEG (FEG:
78.8% (95% CI: 73.3%–83.5%) than FWG: 23.1%
(95%CI: 20.0%–26.4%). Adolescents aged 14–17 years
had also received the recommended booster vaccination
more frequently in FEG (39.5% (95% CI: 34.6%–44.7%))
than in FWG (13.3% (95% CI: 11.0%–16.0%)). Only
10% of 14–17 year olds not vaccinated at a younger age
had received at least one dose of pertussis-containing vac-
cine. In Saxony, vaccination coverage with a 5th vaccine
dose in 7–8 year-old children reached 71.5% in 2006
(unpublished data DB). Vaccination coverage data for the
preschool booster recommended in 2006 in all other
states are unavailable thus far.
Pertussis incidence in former East German States after 
1990 based on surveillance data
Decreasing vaccination coverage after reunification in the
early 1990s in FEG was associated with an increase in per-
Incidence of notified pertussis illness (1947–2007) and hospitalizations (1993–2007) in Germany, (GDR: German Democratic  Republic, FEG: Former East Germany, FWG: Former West Germany) Figure 1
Incidence of notified pertussis illness (1947–2007) and hospitalizations (1993–2007) in Germany, (GDR: Ger-
man Democratic Republic, FEG: Former East Germany, FWG: Former West Germany).
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tussis incidence to 3.4 cases/10000 inhabitants in 1994
(Fig. 1). Following a slight decrease in incidence from
1995 to 1997, pertussis incidence increased further,
despite the STIKO recommendation for a booster vaccina-
tion at the age of 9 to 17 years in 2000 [38]. In 2007 per-
tussis incidence in FEG climbed to 39.3 notified cases/
100.000 inhabitants. Regionally, the increase in incidence
was less marked and occurred later in Saxony-Anhalt (ST)
and TH as compared to BB and MV (Fig. 2). The increase
in incidence after 2002 was most evident in children aged
5 to 9 and 10 to14 years, among whom incidence was
highest, reaching >300 cases/100,000 inhabitants in BB
and MV (Fig. 2). However, the incidence increased in
infants (>3-fold in the five states) and adults as well. In
SN, the overall incidence was lowest and a marked
increase in incidence – most pronounced among 10–14
year olds – did not occur until 2007 (Fig. 2). The propor-
tion of notified pertussis cases reported as hospitalized
from 2002–2007 was lowest in BB (1.9%) and MV (2.2%)
and higher in ST (4.9%), TH (4.1%) and SN (4.6%). Hos-
pitalization was reported for 39.5% of infants <1 year,
4.4% for 1–4 year old children, 1.9% of 5–59 year old
individuals and 5.8% of persons ≥ 60 years.
Sex and age distribution
Available surveillance data from 1995 onwards in FEG
consistently showed a higher pertussis incidence in
females (overall 60% of cases) than in males. This differ-
Pertussis incidence in former East German States 2002–2007 based on notification data according to state-specific infectious  disease surveillance laws Figure 2
Pertussis incidence in former East German States 2002–2007 based on notification data according to state-
specific infectious disease surveillance laws.
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ence was mainly due to a higher proportion of females
among adult cases.
An analysis of the age distribution of cases from 1995 to
2007 in the FEG states reveals a marked decrease in the
proportion of cases among under 5-year olds, and, until
2003, also a decrease in the proportion of cases among
older children and adolescents. While this development
was largely sustained in Saxony until 2006, in the other 4
FEG states the proportion of cases among school children
(5 to 14 year olds) increased markedly in 2004 (Fig. 3a
&3b). The age distribution also shows that the absolute
burden of disease is currently greatest in adults. In Saxony,
the proportion of adults (>19 years of age) among all
cases increased from 16.7% in 1995 to 80.3% in 2005
(subsequently decreasing 67.8% in 2007), while in the
other 4 FEG States this proportion increased more gradu-
ally from 21.1% in 1995 to 68.7% in 2007, also reflected
by the increase in mean age of reported pertussis cases
over time (Fig. 3a &3b)
Vaccination status of pertussis cases reported in former 
East German States, 2004–2007
FEG surveillance data from 2004 onwards reveal a high
proportion of adequately vaccinated cases among chil-
dren aged 6 to 11 years (Fig. 4). Among notified cases with
information on vaccination status in BB, MV; ST and TH,
the proportion of cases aged 6 to 11 years with ≥4 previ-
ous vaccine doses was 59%, 61%, 67% and 68% in 2004
to 2007 respectively, while this was 13%, 22%, 30% and
63% in SN (80/99 adequately vaccinated cases from Sax-
ony were reported in 2007). In BB, MV, ST and TH, only
5.3% (73/1384) of these cases had been vaccinated within
the 3 years preceding their illness; while in SN, this
applied to 27.3% (27/99) of vaccinated cases, most of
which were diagnosed in 2007 (20/27, all by PCR). Of all
4842 cases with at least one documented dose of pertussis
vaccine in FEG from 2004–2007, 746 (15.4%) had been
vaccinated < 3 years prior to illness onset (4.1% of all
notified cases).
Outbreaks
From 2002 to 2007, 16.0% of notified pertussis cases in
FEG were reported as epidemiologically linked; 9.4%
occurred in clusters of 5 or more cases. The largest cluster
that occurred in MV in 2005–2006 consisted of 80 noti-
fied cases, but active case-finding during an outbreak
investigation identified a further 24 persons who fulfilled
the clinical case definition [19]
Pertussis morbidity in both parts of Germany based on 
hospital discharge statistics, mortality data and sentinel 
surveillance in adults
Hospital discharge statistics show a decrease in pertussis
hospitalizations in FEG from 1993 to 2001 with some
fluctuation, decreasing from 1.5 pertussis related hospital-
isations/100.000 population in 1993 to 0.6 in 2001, only
to increase again to 1.7 in 2007 (Fig. 1). The number of
hospitalizations in FWG decreased from 5.6/100000 pop-
ulation in 1993 to a low of 0.8 in 2001, increasing again
to 1.5 in 2005 (Fig. 1). Between 2002 and 2007 the pro-
portion of all pertussis-based hospitalizations among
infants decreased from 66.6% in 2002 to 59.7% in 2007
in FWG, while it fluctuated between 22.5% (2007) and
28.9% (2006) in FEG, with a much higher incidence of
infant hospitalizations in FWG (Fig. 5). Among older chil-
dren and adults, however, incidence of hospitalization for
pertussis was slightly higher in FEG than FWG. From
Age distribution of notified pertussis cases in the former East German States Brandenburg, Mecklenburg Western Pomerania,  Saxony Anhalt and Thuringia (Fig. 3a), and Saxony (Fig. 3b) 1995–2007 Figure 3
Age distribution of notified pertussis cases in the former East German States Brandenburg, Mecklenburg 
Western Pomerania, Saxony Anhalt and Thuringia (Fig. 3a), and Saxony (Fig. 3b) 1995–2007. The total number 
of cases is shown on top of the bars. Age-specific data for 2000 are incomplete and no age specific data are available for 2001.
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2002–2007 in FEG, 69.1% more cases were recorded in
the German Hospital Discharge Statistics (n = 959) than
cases notified as having been hospitalized (n = 567) in the
statutory surveillance system. Until 2007, the incidence of
hospitalized pertussis cases aged <1 year based on hospi-
tal discharge statistics was higher than the total incidence
based on notified cases in FEG (see Fig. 2 and Fig. 5).
Between 1970 and 2007 nine deaths attributed to pertus-
sis were reported in FEG, four of which occurred since
2002, all in elderly adults [39]. In FWG, 231 deaths were
reported in this period, with mortality gradually decreas-
ing. The last three deaths were reported in 2001 in an
infant, in 2005 in an elderly woman and the third in 2007
in a teenager [39]. Mortality is depicted in Figure 1.
Sentinel surveillance in general physician and internist
practices for cough illness lasting at least 7 days in adults
(≥ 18 years) was performed in the FEG city of Rostock and
the FWG city of Krefeld from 2001 to 2004 [40]. Among
the 971 patients recruited to the study, 10% had pertussis
based on a positive PCR of nasopharyngeal aspirate and/
or positive serology (elevated IgA- and IgG-antibodies
against pertussis toxin and filamentous haemagglutinin).
The incidence of pertussis based on this study was esti-
mated at 169 cases/100,000 inhabitants per year in
Krefeld and 160/100.000 inhabitants per year in Rostock,
with an estimated 110.000 cases occurring in adults annu-
ally in Germany. This was 19-fold higher than the mean
incidence in adults based on routine surveillance in FEG
from 2002–2004 of 8.5 cases/100,000 inhabitants respec-
tively.
See additional file 1 for summary of the development of
surveillance practices, vaccination recommendations, vac-
cination coverage and disease burden in the two parts of
Germany.
Discussion
This overview describes markedly different development
of pertussis epidemiology in the two parts of Germany
prior to reunification in 1991. The divergent vaccination
scenarios in the 1970s and 1980s led to a much lower per-
tussis incidence in FEG than FWG. These differences can
be ascribed to limited use of pertussis vaccine in FWG due
to concerns about adverse effects in contrast to continued
high vaccination coverage in FEG. Despite the fact that
severe adverse effects due to pertussis whole cell vaccine
were never substantiated, reports to this effect led to
reduced vaccine uptake and an increase in pertussis mor-
bidity in other countries as well [41].
Analysis of pertussis epidemiology in Germany is limited
in that notification data after 1961 are accessible only
from FEG. Only a partial assessment of the situation in
FWG is possible based on hospital discharge and mortal-
ity data. Moreover, the higher incidence of pertussis cases
in FEG in infants based on hospital discharge statistics
than based on notified cases until 2007 suggests a signifi-
cant degree of underreporting in the FEG statutory surveil-
lance system. Results of sentinel surveillance in a FEG city
[40] also suggest that disease burden in adults is markedly
underestimated by routine surveillance data, likely due to
atypical presentation in persons with pre-existing natural
or vaccine-induced immunity. A further potential limita-
tion of routine surveillance data from FEG lies in the high
proportion of cases diagnosed solely serologically. A
recent study showed that the performance of the most fre-
quently used ELISAs in Germany was variable regarding
antigens used for testing, sensitivity (60–95%), and quan-
Incidence of notified pertussis cases in the former East German States Brandenburg, Mecklenburg Western Pomerania, Saxony  Anhalt and Thuringia (Fig. 4a), and Saxony (Fig. 4b), 2004–2007, according to age and vaccination status Figure 4
Incidence of notified pertussis cases in the former East German States Brandenburg, Mecklenburg Western 
Pomerania, Saxony Anhalt and Thuringia (Fig. 4a), and Saxony (Fig. 4b), 2004–2007, according to age and vac-
cination status.
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titative measurement of antibody levels [42]. Specificity
was not reported, but other studies have shown high spe-
cificities of >90% for ELISAs based on PT- and FHA-anti-
gens [43,44]. The observation that only 4.1% of all
notified cases received a dose of pertussis vaccine < 3 years
prior to illness onset suggests that recent vaccination is
not an explanation for positive serology in the majority of
cases. As well, an analysis of only those cases diagnosed by
culture, PCR or a rise in antibody concentrations showed
similar age distributions and trends over time as did the
analysis of all cases presented here (data not shown).
In addition, the observed epidemiologic patterns, such as
the higher pertussis incidence observed in women than
men in FEG, are consistent with other studies: High per-
tussis-specific IgG-antibodies indicative of recent infec-
tion were found more frequently among women than
men in a seroepidemiological study in England and Wales
[45], and in a household contact study performed in Ger-
many, secondary pertussis cases also occurred more fre-
quently among women than men [46]. Furthermore, the
recent increase in pertussis incidence in FEG associated
with a shift to older age groups mirrors similar develop-
ments in pertussis epidemiology in other western coun-
tries with longstanding vaccination programs [47]. For
instance, in the United States, an increase in incidence was
observed beginning in the 1980s and, starting in the early
1990s, particularly among 10 to 19 year olds [10,48,49]
despite improved vaccination uptake of the preschool
booster [49], thus suggesting waning immunity 5–10
years after the preschool booster.
Correspondingly, despite high vaccination coverage with
the primary vaccination series among FEG preschool chil-
dren in recent years, the incidence of pertussis continued
to increase in the four FEG states that did not recommend
a booster vaccine dose prior to school entry until 2006.
The increase in incidence since 2004 was most marked in
children between 5 and 14 years of age, a high proportion
of whom had received 4 doses of pertussis vaccine in
infancy, suggesting that waning immunity was playing a
role. This is supported by an outbreak investigation per-
Hospitalizations for pertussis per 100.000 inhabitants according to age and residence in former East (FEG) and West (FWG)  Germany, 2002–2007 (Source of data: Statistics of hospital diagnoses, Federal Statistical Office, available at http://www.gbe- bund.de/gbe10/abrechnung.prc_abr_test_logon?p_uid=gast&p_aid=&p_sprache=D&p_knoten=VR&p_suchstring=pertussis Figure 5
Hospitalizations for pertussis per 100.000 inhabitants according to age and residence in former East (FEG) and West (FWG) 
Germany, 2002–2007 (Source of data: Statistics of hospital diagnoses, Federal Statistical Office, available at http://www.gbe-
bund.de/gbe10/abrechnung.prc_abr_test_logon?p_uid=gast&p_aid=&p_sprache=D&p_knoten=VR& 
p_suchstring=pertussis.
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formed in a highly vaccinated school population in Meck-
lenburg Western-Pomerania in 2006, which showed a
markedly higher attack rate in children who had received
their fourth vaccine dose >5 years previously [19].
Increased vaccination coverage may lead to a period of
decreased natural boosting, which may "unmask" the
effect of waning vaccine-induced immunity, causing inci-
dence to increase despite a lower level of transmission.
Modeling studies suggest that the severity of disease – and
thus the diagnostic threshold – depends on the level of
transmission, with a higher incidence of severe disease
expected at intermediate transmission intensities [50].
Thus an overall reduction in transmission initiated
through increased vaccination coverage could theoreti-
cally lead to a higher incidence of more severe – and there-
fore recognized – disease through a combination of
waning immunity and less natural boosting.
An increase in pertussis incidence in Saxony, where a pre-
school booster was recommended since 1998, occurred in
2007. Although all age groups were affected, the increase
was most pronounced in children aged 10 to 14 years,
suggesting that uptake of the adolescent booster vaccina-
tion may be insufficient or occurring too late. The Saxony
state health authority also increased awareness for the
diagnosis of pertussis among physicians by actively
informing about the possibility of PCR diagnosis at the
state-run microbiological laboratory in 2007 (personal
communication, DB). This, along with the higher propor-
tion of cases diagnosed < 3 years after the primary vacci-
nation series in 2007, suggests that a change in diagnostic
practices might partially explain the observed increase.
The incidence in Saxony still remains lower than that in
all other FEG states (Fig. 2) and the increase in 2007 may
also in part be due to periodic variation in incidence.
The continued increase in pertussis incidence in FEG
despite improved vaccine uptake after the mid-1990s also
coincided with widespread introduction of acellular vac-
cines in Germany. Thus another possible explanation
might be a shorter duration of immunity compared to
vaccination with whole cell vaccines. In FEG, the pertussis
component of the combined diphtheria, tetanus, pertussis
vaccine consisted of alum-adsorbed B. pertussis (30–40 ×
109 bacteria/ml), equivalent to at least 4 international
potency units per 0.5 ml dose [20,51], fulfilled interna-
tional potency requirements of at least 4 IPU issued by the
World Health Organization in 1964 [52]. In general,
available studies suggest a similar duration of immunity
after vaccination with acellular and whole cell vaccines
[53], although comparison is difficult due to the heteroge-
neity of both vaccine types, and inability to control for cir-
culating levels of pertussis in the population, which could
influence immunity through natural boosting.
The higher incidence of hospitalization due to pertussis in
infants in FWG than FEG suggests a higher level of disease
transmission in FWG, in keeping with lower vaccination
coverage particularly in older children and adolescents,
who along with adults presumably act as a transmission
reservoir for infants [54-58]. However, the slightly higher
incidence of pertussis-related hospitalizations in FEG in
older children and adolescents, who have higher vaccina-
tion coverage than their counterparts in FWG, is surpris-
ing. A higher incidence of pertussis hospitalizations in
FEG than FWG was also found during intensified hospi-
tal-based surveillance for pertussis complications in chil-
dren under 16 years in 1997–1998 [59]. Possible
explanations could be a lower hospitalization threshold
in FEG, perhaps due to a lower density of physicians in
private practice than in FWG [60] or a higher degree of
awareness for the diagnosis.
Sentinel surveillance in two cities in FWG and FEG [40]
suggests that pertussis incidence in the two parts of Ger-
many is similar in adults despite the lack of childhood
vaccination in FWG prior to 1991. Adults in FEG vacci-
nated in childhood presumably experienced less natural
boostering than non-vaccinated adults in FWG, who
would have experienced natural infection – thought to
induce longer lasting immunity than vaccination – in
childhood more frequently than in FEG. Thus, FEG adults
might be expected to be more susceptible to pertussis than
FWG adults. This could explain the similar incidence in
adults in the two parts of Germany despite evidence for a
higher level of Bordetella pertussis transmission in FWG.
This is corroborated by a seroprevalence study performed
in several European countries including FWG and FEG in
the mid-1990s [61,62], which revealed that overall, adults
were less likely to have high pertussis-toxin antibody
(anti-PT) concentrations suggestive of recent acute infec-
tion than younger persons. However, in countries with a
history of high vaccination coverage (The Netherlands,
Finland and FEG), adults comprised a higher proportion
of cases with recent pertussis infection than in countries
with low vaccination coverage (France, FWG, United
Kingdom, and Italy). Thus, in the mid-1990s adults were
0.6 times less likely to have high anti-PT than children
and adolescents in FEG, but 0.3 times less likely in FWG.
While this difference in age distribution in the two parts
of Germany has likely narrowed, the markedly higher
incidence of hospitalizations for pertussis in infants and
lower vaccination coverage among adolescents in FWG
suggest that differences in epidemiologic pattern persist.
Furthermore, differences in contact patters, another deter-
minant of infectious disease transmission [63], likely also
exist. For instance, one difference between FEG and FWG
in this regard is the higher proportion of children attend-
ing day care in FEG, even close to 20 years after reunifica-
tion. In FEG states, day care attendance of children < 3BMC Infectious Diseases 2009, 9:22 http://www.biomedcentral.com/1471-2334/9/22
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years of age in 2007 ranged from 31.7% in Saxony to
51.4% in Saxony-Anhalt, but from 5,2% to 36,1% in FWG
states [64], with less extreme differences in older children.
Such differences could influence disease transmission pat-
terns between children as well as from children to adults.
However, this remains hypothetical without robust sur-
veillance data from both parts of Germany.
Conclusion
Nationwide pertussis reporting is urgently required to bet-
ter understand disease transmission patterns, for early rec-
ognition, control and prevention of outbreaks and for the
evaluation of vaccination policy. Universal recommenda-
tion for an additional pertussis booster vaccination at the
age of 5 to 6 years since 2006 is expected to decrease mor-
bidity in older children. In keeping with recommenda-
tions of the Global Pertussis Initiative [65], improved
uptake of the recommended adolescent booster as well as
vaccination of persons with close contact to infants is cru-
cial to further reduce morbidity. The high proportion of
cases in adults suggests a need for additional booster vac-
cinations.
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